Facebook
X
LinkedIn
Forward
ROBIN Oligometastasis (OligoMET) Center: Using Biomarker Correlates from a Prostate Cancer Clinical Trial to Improve Future Outcomes
Metastasis is the final common lethal pathway for most cancer patient's demise and once cancer has metastasized, it was generally considered incurable. We now know the metastatic capacity of cancer behaves along a spectrum of disease that contains an oligometastatic state where metastases are limited. This concept has been transformational in the way the clinical field views metastasis; however, a greater biologic understanding is needed. This in turn will lead to the development of new approaches for using radiation therapy to combat metastases. The NCI U54 ROBIN Oligometastasis (OligoMET) Center was created for greater adoption of radiation oncology concepts, biomarkers, and technologies in the oligometastatic space through academic and/or industrial partnerships. The OligoMET Center uses oligometastatic prostate cancer as our model, but results will inform future treatment planning and trial design in other cancers. This activity delves into breakthrough findings from the ROBIN OligoMET Center. The activity explores how specific biomarkers from prostate cancer clinical trials are used to probe the biological nuances of oligometastatic states, focusing on the effects of radiation on tumor plasticity, metabolic reprogramming, and the immune microenvironment. Radiation oncologists gain insights into the emerging paradigm where precise radiation treatments not only target tumors but may also recondition the tumor biology, potentially leading to improved patient outcomes. By examining the intersection of biomarker data and radiation's impact on metastasis, this activity paves the way for innovative trial designs and collaborative advancements in treating oligometastatic disease across various cancers.
Topics:
- Radiation Oncology-Biology Integration Network (ROBIN) - Oligometastasis Center
Phuoc T. Tran, MD, PhD - The Genomic Landscape of Castration-sensitive Prostate Cancer: Biomarkers to Direct Local Therapy
Matthew Pierre Deek, MD - Digital Pathology-based Multimodal Artificial Intelligence Biomarker in Oligometastatic Castration-sensitive Prostate Cancer
Philip Sutera, MD - Q and A
Phuoc T. Tran, MD, PhD – Moderator
Full Panel
This activity is available from March 31, 2026, through 11:59 p.m. Eastern time on March 30, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, pathologists, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Analyze the biology of oligometastatic prostate cancer. Learners will assess how radiation affects tumor plasticity, metabolism, and the immune microenvironment, and integrate biomarker data from clinical trials to inform evaluation and treatment decisions for metastatic disease.
- Evaluate biomarker-driven strategies to enhance radiation efficacy in oligometastatic cancer. Learners will assess findings from the ROBIN OligoMET trials and apply biomarker insights to personalize radiation plans, improve outcomes, and explore broader applications across cancer types.
- Implement strategies to integrate radiation into cancer management for oligometastatic disease. Learners will use biomarkers to guide protocol adjustments and demonstrate the ability to design adaptable, radiation-inclusive treatment plans informed by current metastatic disease biology.
Moderator:
- Phuoc T. Tran, MD, PhD, is employed by MD Anderson Cancer Center. Dr. Tran receives honoraria from Bayer Healthcare, Janssen, Natsar Pharmaceuticals and RefleXion Medical Inc. Dr. Tran owns a copyright/patent with Natsar Pharmaceuticals.
Speakers:
- Matthew Pierre Deek, MD, is employed by Rutgers Cancer Institute. Dr. Deek has no relevant financial relationship with ineligible companies to disclose.
- Philip Sutera, MD, is employed by Rutgers University. Dr. Sutera has no relevant financial relationship with ineligible companies to disclose.
- Phuoc T. Tran, MD, PhD, is employed by MD Anderson Cancer Center. Dr. Tran receives honoraria from Bayer Healthcare, Janssen, Natsar Pharmaceuticals and RefleXion Medical Inc. Dr. Tran owns a copyright/patent with Natsar Pharmaceuticals.
Planners:
- Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until March 30, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.